Cargando…

Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk

Detalles Bibliográficos
Autores principales:	Lesniak, Robert K., Nichols, R. Jeremy, Montine, Thomas J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643380/ https://www.ncbi.nlm.nih.gov/pubmed/36388213 http://dx.doi.org/10.3389/fneur.2022.1016040

Ejemplares similares

Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson's disease
por: Warø, Bjørg Johanne, et al.
Publicado: (2017)

A More Homogeneous Phenotype in Parkinson's Disease Related to R1441G Mutation in the LRRK2 Gene
por: Vinagre-Aragón, Ana, et al.
Publicado: (2021)

Precision medicine: Clarity for the clinical and biological complexity of Alzheimer’s and Parkinson’s diseases
por: Montine, Thomas J., et al.
Publicado: (2015)

Subthalamic Peak Beta Ratio Is Asymmetric in Glucocerebrosidase Mutation Carriers With Parkinson's Disease: A Pilot Study
por: David, Fabian J., et al.
Publicado: (2021)

Precision medicine in Parkinson’s disease: emerging treatments for genetic Parkinson’s disease
por: Schneider, Susanne A., et al.
Publicado: (2020)

Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease
por: Smith, Laura J., et al.
Publicado: (2022)

Four-Year Longitudinal Study of Motor and Non-motor Symptoms in LRRK2-Related Parkinson's Disease
por: Deng, Xiao, et al.
Publicado: (2020)

Novel Variants in LRRK2 and GBA Identified in Latino Parkinson Disease Cohort Enriched for Caribbean Origin
por: Nuytemans, Karen, et al.
Publicado: (2020)

Longitudinal evaluation of olfactory function in individuals with Gaucher disease and GBA1 mutation carriers with and without Parkinson's disease
por: Lopez, Grisel J., et al.
Publicado: (2022)

LIPAD (LRRK2/Luebeck International Parkinson's Disease) Study Protocol: Deep Phenotyping of an International Genetic Cohort
por: Usnich, Tatiana, et al.
Publicado: (2021)

Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson’s disease
por: Gomes, Sara, et al.
Publicado: (2023)

Sleep Spindles and Fragmented Sleep as Prodromal Markers in a Preclinical Model of LRRK2-G2019S Parkinson's Disease
por: Crown, Lindsey M., et al.
Publicado: (2020)

Resting-State Cerebello-Cortical Dysfunction in Parkinson's Disease
por: Palmer, William C., et al.
Publicado: (2021)

Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers
por: Zhao, Ye, et al.
Publicado: (2018)

Generalized dystonia without Parkinsonism in an LRRK2 carrier
por: Díaz-Feliz, Lola, et al.
Publicado: (2022)

Application of Precision Medicine in Neurodegenerative Diseases
por: Strafella, Claudia, et al.
Publicado: (2018)

Precision Medicine for Intracranial Atherosclerotic Disease
por: Liebeskind, David S.
Publicado: (2021)

Effect of LRRK2 G2385R Variant on Subthalamic Deep Brain Stimulation Efficacy in Parkinson's Disease in a Han Chinese Population
por: Chen, Si, et al.
Publicado: (2019)

Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson’s Disease
por: Ito, Genta, et al.
Publicado: (2023)

Differences in EEG Event-Related Potentials during Dual Task in Parkinson’s Disease Carriers and Non-Carriers of the G2019S-LRRK2 Mutation
por: Shkury, Eden, et al.
Publicado: (2023)

Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2
por: Deng, Xianming, et al.
Publicado: (2011)

Fibroblast Biomarkers of Sporadic Parkinson’s Disease and LRRK2 Kinase Inhibition
por: Smith, G. A., et al.
Publicado: (2015)

Rab29 activation of the Parkinson's disease‐associated LRRK2 kinase
por: Purlyte, Elena, et al.
Publicado: (2017)

Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson’s disease
por: Gonzalez-Hunt, C. P., et al.
Publicado: (2020)

Sex effects on clinical features in LRRK2 G2385R carriers and non-carriers in Parkinson's disease
por: Cui, Shi-Shuang, et al.
Publicado: (2021)

Epitope Mapping of Antibodies to Alpha-Synuclein in LRRK2 Mutation Carriers, Idiopathic Parkinson Disease Patients, and Healthy Controls
por: Alvarez-Castelao, Beatriz, et al.
Publicado: (2014)

Association of caffeine and related analytes with resistance to Parkinson disease among LRRK2 mutation carriers: A metabolomic study
por: Crotty, Grace F., et al.
Publicado: (2020)

Inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2) Protect Against LRRK2-Models of Parkinson’s Disease
por: Lee, Byoung Dae, et al.
Publicado: (2010)

Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism
por: Chittoor-Vinod, Vinita G., et al.
Publicado: (2021)

Precision medicine in Parkinson’s disease patients with LRRK2 and GBA risk variants – Let’s get even more personal
por: von Linstow, Christian U., et al.
Publicado: (2020)

LRRK2 and Proteostasis in Parkinson’s Disease
por: Pérez-Carrión, María Dolores, et al.
Publicado: (2022)

Targeting LRRK2 in Parkinson’s disease
por: Xiao, Bin, et al.
Publicado: (2022)

Serotonin transporter binding and motor onset of Parkinson's disease in asymptomatic LRRK2 mutation carriers: a cross-sectional study
por: Wile, Daryl J, et al.
Publicado: (2017)

Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers
por: Wang, Shijie, et al.
Publicado: (2017)

14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization
por: Nichols, R. Jeremy, et al.
Publicado: (2010)

Sensorimotor Inhibition and Mobility in Genetic Subgroups of Parkinson's Disease
por: Martini, Douglas N., et al.
Publicado: (2020)

A leucine‐rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls
por: Vissers, Maurits F. J. M., et al.
Publicado: (2023)

Association Between Glucocerebrosidase Mutations and Parkinson's Disease in Ireland
por: Olszewska, Diana A., et al.
Publicado: (2020)

Differential Phospho‐Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease
por: Garrido, Alicia, et al.
Publicado: (2022)

Differential serum microRNAs in premotor LRRK2 G2019S carriers from Parkinson’s disease
por: Soto, Marta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_amacec6fqb9cejfokkk32q1vim